| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Joel Michael Maryles last filed a Form 4 in May 2022, as Director at CMMB. Joel Michael Maryles's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,433 shares of CMMB. Net of sales, the CMMB filings show accumulation of 1,433 shares.
Joel Michael Maryles has 4 Form 4 filings on record from April 2021 to May 2022, all as Director at Chemomab Therapeutics (CMMB), 2021–2022.
The 11 reported transactions were 7 option or other derivative awards and 4 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $6K and no sales.
The largest open-market purchase was 1,000 shares of CMMB at an average $4.34 on March 18, 2022, about $4K. Twelve months later CMMB was down 67%.
Shares as reported in the last Form 4 for each company; the most recent is from May 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.